Cover Image
市場調查報告書

糖尿病治療藥市場:各產品(注射劑及口服抗糖尿病藥物) - 全球機會分析及產業預測

Diabetes Therapeutics Market by Product (Injectables and Oral-antidiabetic Drugs) - Global Opportunity Analysis and Industry Forecast, 2017-2023

出版商 Allied Market Research 商品編碼 563374
出版日期 內容資訊 英文 170 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
糖尿病治療藥市場:各產品(注射劑及口服抗糖尿病藥物) - 全球機會分析及產業預測 Diabetes Therapeutics Market by Product (Injectables and Oral-antidiabetic Drugs) - Global Opportunity Analysis and Industry Forecast, 2017-2023
出版日期: 2017年08月01日 內容資訊: 英文 170 Pages
簡介

本報告提供全球糖尿病治療藥市場相關調查,彙整市場趨勢與各產品,各地區趨勢,及打入市場的主要企業簡介等資料。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義和範圍
  • 主要調查結果
  • 市場佔有率分析
  • 市場趨勢
    • 促進要素
    • 阻礙要素
    • 機會
    • 影響分析
  • 臨床實驗

第4章 各產品市場

  • 概要
    • 市場規模與預測
  • 注射劑
    • 胰島素
    • 胰高血糖素樣肽1(GLP-1)受體激動劑
    • Amylin模仿藥
  • 口服抗糖尿病藥物
    • 雙胍類(Biguanides)
    • 磺醯尿素類
    • 胰島素增敏劑
    • AlphaGlucosidase抑制劑
    • DDP-4(DPP-4)抑制劑
    • Meglitinide
    • SGLT2抑制劑

第5章 各地區市場

  • 概要
  • 北美
  • 歐洲
  • 亞太地區
  • 南美

第6章 企業簡介

目錄
Product Code: LI 173542

The global diabetes therapeutics market was valued at $66,993 million in 2016, and is estimated to reach $186,842 million by 2023, growing at a CAGR of 16.0% from 2017 to 2023. Diabetes therapeutics are drugs used by diabetic patients to restore the blood glucose metabolism to a normal state.

The factors that drive the global diabetes therapeutics market include rise in geriatric population, increase in prevalence of diabetes worldwide, sedentary lifestyle of people, development of affordable & effective diabetes therapeutics, growth in awareness among people about self-management of diabetes, and support from the government However, side effects of diabetic drugs and stringent approval process for the same restrict the market growth. Moreover, surge in awareness about diabetes care and market potential in developing regions are expected to provide numerous opportunities for market growth.

The global diabetes therapeutics market is segmented on the basis of product and region. Based on product, it is bifurcated into injectable and oral-antidiabetic drugs (OAD). Injectable are further categorized into insulin, glucagon-like peptide-1 (GLP-1) receptor agonists, and amylinomimetic drug. Oral-antidiabetic drugs (OAD) segment is further divided into biguanides, sulfonylureas, thiazolidinediones, alpha-glucosidase inhibitors, dipeptidyl peptidase IV (DPP-4) inhibitors, meglitinides, and sodium-glucose cotransporter-2 (SGLT2) inhibitors. Based on region, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, Italy, UK, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the market with current trends and future estimations from 2016 to 2023 to elucidate the imminent investment pockets.
  • Comprehensive analysis of factors that drive and restrict the growth of the market is provided.
  • Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global and regional scale are provided.
  • Key market players are profiled and their strategies are analyzed thoroughly, which help understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

BY PRODUCT

  • Injectables
  • Insulin
  • Glucagon-like Peptide-1 (GLP-1) Receptor Agonists/Incretin Mimetics
  • Amylin Analogue/Amylinomimetic Drugs
  • Oral-antidiabetic Drugs (OAD)
  • Biguanides
  • Sulfonylureas
  • Thiazolidinediones
  • Alpha-glucosidase Inhibitors
  • Dipeptidyl Peptidase IV (DPP-4) Inhibitors/Gliptins
  • Meglitinides
  • Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors/Gliflozins

BY REGION

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
  • LIST OF KEY PLAYERS PROFILED IN THE REPORT
  • AstraZeneca plc
  • Boehringer Ingelheim GmbH
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
  • Astellas Pharma Inc.
  • Biocon Limited
  • Diasome Pharmaceuticals, Inc.
  • Generex Biotechnology Corp.
  • MannKind Corporation
  • Pfizer Inc.

Table of Contents

CHAPTER 1 INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. KEY BENEFITS FOR STAKEHOLDERS
  • 1.3. KEY MARKET SEGMENTS
  • 1.4. RESEARCH METHODOLOGY
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

  • 2.1. KEY FINDINGS OF THE STUDY
  • 2.2. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

  • 3.1. MARKET DEFINITION AND SCOPE
  • 3.2. KEY FINDINGS
    • 3.2.1. Top investment pockets
    • 3.2.2. Top winning strategies
      • 3.2.2.1. Competitive intelligence of companies and their strategies
  • 3.3. MARKET SHARE ANALYSIS, 2016
  • 3.4. MARKET DYNAMICS
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities
    • 3.4.4. Impact analysis
  • 3.5. CLINICAL TRIALS

CHAPTER 4 GLOBAL DIABETES THERAPEUTICS MARKET, BY PRODUCT

  • 4.1. OVERVIEW
    • 4.1.1. Market size and forecast
  • 4.2. INJECTABLES
    • 4.2.1. Insulin
      • 4.2.1.1. Market size and forecast
    • 4.2.2. Glucagon-like peptide-1 (GLP-1) receptor agonists
      • 4.2.2.1. Market size and forecast
    • 4.2.3. Amylinomimetic drug
      • 4.2.3.1. Market size and forecast
    • 4.2.4. Key market trends
    • 4.2.5. Growth factors and opportunities
    • 4.2.6. Market size and forecast
  • 4.3. ORAL-ANTIDIABETIC DRUGS (OAD)
    • 4.3.1. Biguanides
      • 4.3.1.1. Market size and forecast
    • 4.3.2. Sulfonylureas
      • 4.3.2.1. Market size and forecast
    • 4.3.3. Thiazolidinediones
      • 4.3.3.1. Market size and forecast
    • 4.3.4. Alpha-glucosidase inhibitors
      • 4.3.4.1. Market size and forecast
    • 4.3.5. Dipeptidyl Peptidase IV (DPP-4) inhibitors
      • 4.3.5.1. Market size and forecast
    • 4.3.6. Meglitinides
      • 4.3.6.1. Market size and forecast
    • 4.3.7. Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors
      • 4.3.7.1. Market size and forecast
    • 4.3.8. Key market trends
    • 4.3.9. Growth factors and opportunities
    • 4.3.10. Market size and forecast

CHAPTER 5 DIABETES THERAPEUTICS MARKET, BY REGION

  • 5.1. OVERVIEW
    • 5.1.1. Market size and forecast
  • 5.2. NORTH AMERICA
    • 5.2.1. Key market trends
    • 5.2.2. Key growth factors and opportunities
    • 5.2.3. Market size and forecast
    • 5.2.4. U.S.
    • 5.2.5. Canada
    • 5.2.6. Mexico
  • 5.3. EUROPE
    • 5.3.1. Key market trends
    • 5.3.2. Key growth factors and opportunities
    • 5.3.3. Market size and forecast
    • 5.3.4. Germany
    • 5.3.5. France
    • 5.3.6. UK
    • 5.3.7. Italy
    • 5.3.8. Spain
    • 5.3.9. Rest of Europe
  • 5.4. ASIA-PACIFIC
    • 5.4.1. Key market trends
    • 5.4.2. Key growth factors and opportunities
    • 5.4.3. Market size and forecast
    • 5.4.4. Japan
    • 5.4.5. China
    • 5.4.6. India
    • 5.4.7. Australia
    • 5.4.8. South Korea
    • 5.4.9. Rest of Asia-Pacific
  • 5.5. LAMEA
    • 5.5.1. Key market trends
    • 5.5.2. Key growth factors and opportunities
    • 5.5.3. Market size and forecast
    • 5.5.4. Brazil
    • 5.5.5. South Africa
    • 5.5.6. Saudi Arabia
    • 5.5.7. Rest of LAMEA

CHAPTER 6 COMPANY PROFILES

  • 6.1. ASTRAZENECA PLC
    • 6.1.1. Company overview
    • 6.1.2. Operating business segments
    • 6.1.3. Business performance
    • 6.1.4. Key strategic moves and developments
  • 6.2. BOEHRINGER INGELHEIM GMBH
    • 6.2.1. Company overview
    • 6.2.2. Operating business segments
    • 6.2.3. Business performance
    • 6.2.4. Key strategic moves and developments
  • 6.3. ELI LILLY AND COMPANY
    • 6.3.1. Company overview
    • 6.3.2. Operating business segments
    • 6.3.3. Key strategic moves and developments
  • 6.4. GLAXOSMITHKLINE PLC
    • 6.4.1. Company overview
    • 6.4.2. Operating business segments
    • 6.4.3. Business performance
    • 6.4.4. Key strategic moves and developments
  • 6.5. JOHNSON & JOHNSON
    • 6.5.1. Company overview
    • 6.5.2. Operating business segments
    • 6.5.3. Business performance
    • 6.5.4. Key strategic moves and developments
  • 6.6. MERCK & CO., INC.
    • 6.6.1. Company overview
    • 6.6.2. Operating business segments
    • 6.6.3. Business performance
    • 6.6.4. Key strategic moves and developments
  • 6.7. NOVARTIS AG
    • 6.7.1. Company overview
    • 6.7.2. Operating business segments
    • 6.7.3. Business performance
    • 6.7.4. Key strategic moves and developments
  • 6.8. NOVO NORDISK
    • 6.8.1. Company overview
    • 6.8.2. Operating business segments
    • 6.8.3. Business performance
    • 6.8.4. Key strategic moves and developments
  • 6.9. SANOFI S.A.
    • 6.9.1. Company overview
    • 6.9.2. Operating business segments
    • 6.9.3. Business performance
    • 6.9.4. Key strategic moves and developments
  • 6.10. TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • 6.10.1. Company overview
    • 6.10.2. Operating business segments
    • 6.10.3. Business performance
    • 6.10.4. Key strategic moves and developments
Back to Top